Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancerwith MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-worldoverall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n=55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1months. Among radiation-naive patients on 1L capmatinib (n=20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1months. Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients. We evaluated #realworld outcomes for patients with #NSCLC with METex14 mutation and brain metastases, treated with capmatinib in clinical practice. We found substantial systemic and intracranial effectiveness with first-line capmatinib therapy.

Authors

Publication Details

Journal
Figshare
Published
2026-11-13
DOI
https://doi.org/10.6084/m9.figshare.35003952
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Keith L. Davis, Paul K. Paik, Mark A Price, Teddy Rassem Saliba et al.
2 links
Figshare
Lung Cancer Treatments and Mutations
article

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Keith L. Davis, Paul K. Paik, Mark A Price, Teddy Rassem Saliba, Beilei Cai, Valérie Derrien Ansquer, RK Goyal, Nydia Caro
article en

Abstract

Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancerwith MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-worldoverall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n=55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1months. Among radiation-naive patients on 1L capmatinib (n=20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1months. Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients. We evaluated #realworld outcomes for patients with #NSCLC with METex14 mutation and brain metastases, treated with capmatinib in clinical practice. We found substantial systemic and intracranial effectiveness with first-line capmatinib therapy.

Figshare
Good health and well-being
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon